Gyros appoints Erik Walldén as CEO


The instrument company Gyros AB (Gyros), based in Uppsala, Sweden, has appointed Erik Walldén as President and CEO. He will replace Lars Eric Utterman, who will join the board of Gyros after a successful year as acting CEO.

Erik Walldén will assume his new role on March 1, 2009. He has extensive experience within the biotech supply industry. In particular, his skills in the areas of international sales and strategic marketing will be key assets to Gyros during its current market-expansion phase.

Erik Walldén has, during his career, held several positions at executive level: most recently as CEO of Affibody Holding AB; and prior to that, as CEO of Biacore International AB and Pyrosequencing AB. Walldén is a member of the Industrial Supervisory Board of HealthInvest Partners AB, and a non-executive director of Exiqon A/S, Proxeon A/S and VisEn Medical Inc.

“I am very pleased with the recruitment of Erik as Gyros´ new CEO. He has in the past shown that he can successfully develop companies and create long term value for the owners as well as for the customers,” stated Per Carendi, chairman of Gyros and CEO of Scandinavian Life Science Ventures. “Gyros has now reached a stage where its technology is established in the market, and the first signs of market pull can be seen. The recruitment of Erik is also a proof of our strong belief in Gyros and the possibilities to further grow the business,” he concludes.

For Gyros AB

Katie Odgaard / Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947 / +44 (0) 7811 996 942
Skype: kodgaard / lorna.cuddon
Email: /

Notes to editors:
About Gyros (

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.

Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nano-liter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.

The company is based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors.